Is anyone able to comment on when ISMP's Guideline "Guidelines for Safe Medication Use in Perioperative and Procedural Settings" expected to be finalized?

Hello all,
Anyone willing to share their pump entries for KCentra? We are looking to update our entries to 2 separate weight range entries and would like to see how others program their pumps as we look to make the entries more nursing friendly.
Thanks,
Kyra

Hello all!

I’d like to hear what your experience is with usage of smart pump interoperability for carrier fluids and if you found ways to successfully accommodate nursing workflow.

A large amount of our non-compliant pump programming cases are related to normal saline for use with IVPBs. There are either zero attempts or failed attempts with ‘order has not been verified by pharmacy’ errors.

We are experiencing increased use of LR as maintenance fluids. How are institutions handling Y-site administration of ceftriaxone with LR? Trissel’s does show one study compatible for 4 hours with ceftriaxone 100 mg/ml y-site administration with LR, but all other studies incompatible.
Do you allow Y-site administration of ceftriaxone with LR?
Do you recommend a flush before and after to mitigate potential precipitation?
If so, what volume is sufficient to flush for compatibility concerns?

We are reviewing our sterile compounding policies and are curious how other hospitals are handling fake eyelashes.

Do you specifically identify and prohibit the use of fake eyelashes in your Sterile Compounding Policies?

If no, do you consider fake eyelashes a "cosmetic" and require that they are removed prior to entering sterile compounding area?

Hello there!

(diving into our Ambulatory BCMA journey here...)

Do you currently wristband patients in your Ambulatory clinics?
If yes, do you wristband all patients or certain subsets of patients? (which subsets of patients / how do you determine if patient needs a wristband?)

Thanks in advance!
Emily

In reviewing some data on IV contrast I am finding that there is no cross-reactivity for these agents in patients with shellfish or iodine allergies, despite a common belief that there is.

From the 2022 American College of Radiology Manual on Contrast Media:

Hello,

Do you have any policy/procedures at your institution requiring an RN to complete an in person handoff with heparin infusions (current rate, last ptt, last titration, etc) when the patient transfers, much like a controlled substance chain of custody handoff.

Your responses are appreciated,
Mara

Our nephrology team is encouraging a shift towards Cystatin C-based eGFR for drug dosing. One of our concerns is around practicing "off-label" since most FDA approved dosing is based on CrCl cut-offs. Has this been evaluated at your institution? Please select the options that match your practice, and feel free to expand upon your response in comments:

1) Serum cystatin C (Scys)-based eGFR is used for renal drug adjustment in place of Serum Creatinine (SCr)-based eGFR

Updating our stop date policy. We do NOT consider propofol a controlled substance, nor do we impose a stop date. Do any of your organizations impose a stop date if you don't consider propofol a controlled substance?